Clinical trial NCT04862715: The Iron and Muscle Study
Official title: Multicentre Prospective Double-blind Randomised Controlled Trial of the Effect of Intravenous Iron Supplementation and Exercise Training in Iron-deficient, But Not Anaemic, Patients With Chronic Kidney Disease on Exercise Capacity, Physical Function, Fatigue, and Skeletal Muscle Metabolism
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: CKD Stage 3
CKD Stage 4
Iron-deficiency
Lead sponsor: King's College Hospital NHS Trust
Sponsor class: OTHER
Collaborators: name: King's College London
name: University of Leicester
First posted: 2021-04-28
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multi-center randomized controlled trial that will examine the efficacy of IV iron supplementation when compared to placebo, with and without exercise training, on changes in patient exercise capacity. The study aims to provide sufficient data to inform a power calculation for the definitive study to examine whether IV iron therapy in patients with CKD stages 3-4 (non-dialysis) can improve exercise capacity, muscle metabolism and physical function. Specifically, we propose to examine whether a strategy of IV iron therapy in patients with stages 3-4 CKD who are iron-deficient but NOT anaemic leads to improvements in exercise capacity.

Very little is currently known about the effects of iron deficiency on cardiac or skeletal muscle metabolism in patients suffering from CKD. Nevertheless, it seems likely that iron deficiency will contribute to mitochondrial dysfunction and reduced energy production in cardiac or skeletal muscle of CKD patients, and importantly may contribute to the reduced exercise capacity, physical function and overwhelming fatigue commonly reported in this population. The results of this trial will provide data to ascertain whether intravenous iron therapy might be beneficial to exercise capacity, muscle metabolism, physical function, and fatigue and whether iron repletion enhances the effect of an exercise intervention.


Eligibility criteria: Inclusion Criteria:

* Patients with established CKD (Stages 3-4) not on dialysis
* Resting BP ≤ 160/95mmHg
* Men and women aged 18 - 80 years
* Serum ferritin level less than 100μg/L AND/OR transferrin saturation ≤20%
* Haemoglobin 110 - 150 g/L

Exclusion Criteria:

* Pregnancy or breast feeding (Female patients of childbearing age will be asked if there is any possibility they may be pregnant. This is standard of care and no pregnancy test will be requested unless there is doubt about this. IV iron is given to many pregnant patients in standard treatment and there is no evidence of harm to mother or foetus).
* Weight \< 50kg
* Known allergy to iron therapy
* Haemochromatosis, porphyria cutanea tarda or history of acquired iron overload
* Intravenous iron within previous 6 weeks
* CRP \> 50 mg/L
* Serum phosphate \< 0.7 mmol/L.
* Active infection
* Current therapy with ESAs
* Uncontrolled atrial fibrillation
* Use of anticoagulants in those under consideration for muscle biopsy
* Unstable angina or heart attack within the last year
* Presence of solid organ cancer
* Known haemoglobinopathy, myelodysplasia, or myeloma
* Patients with peripheral vascular or musculoskeletal disease, who the investigator deems unable to carry out the 6MWT.
* Known severe aortic stenosis and pacemaker in-situ
* History of severe atopy
* Severe liver disease with serum transaminases \> x3 upper limit of normal range according to local laboratory values.
* Severe lung disease with FEV1 known to be \<50% predicted in last year
* Known heart failure with a left ventricular ejection fraction \<45% in last year
* Any other health condition considered by the local Principal Investigator in which IV iron will be contraindicated.
* Insufficient understanding of the trial

Primary outcomes:
measure: Exercise capacity as measured by 6 minute walk distance (6MWD)
timeFrame: 4 weeks
Secondary outcomes:
measure: Haemoglobin levels
timeFrame: 12 weeks
measure: Iron status
timeFrame: 12 weeks
measure: Renal function
timeFrame: 12 weeks
measure: VO2 peak test (in a sub-set of participants)
timeFrame: 12 weeks
measure: Isokinetic dynamometry (muscle strength)
timeFrame: 12 weeks
measure: Functional capacity
timeFrame: 12 weeks
measure: KDQOL-36
timeFrame: 12 weeks
measure: Skeletal muscle phosphocreatine recovery halftime (PCr t1/2) on MRI spectroscopy (n=40 patients at baseline and 4 weeks)
timeFrame: 12 weeks
measure: The Work and Social Adjustment Scale (WSAS)
timeFrame: 12 weeks
measure: To assess the impact of iron regulatory genes e.g. HFE, TMPRSS6 etc. on the primary and secondary endpoints of the study (exploratory only)
timeFrame: 12 Weeks
measure: Iron Status
timeFrame: 12 weeks
measure: Renal Function
timeFrame: 12 weeks
measure: Renal Function
timeFrame: 12 weeks
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: King's College Hospital NHS Foundation Trust
Study officials:
affiliation: Kings College Hospital NHS Foundation Trust
name: Kate Bramham
role: PRINCIPAL_INVESTIGATOR
References: